OCC head promises final GENIUS rules by November

cointelegraphPublicado a 2026-08-19Actualizado a 2026-08-19

Resumen

The head of the Office of the Comptroller of the Currency (OCC), Jonathan Gould, has committed to releasing final rules for implementing the GENIUS Act by November. Speaking at an industry symposium, Gould stated the OCC is considering feedback on its February proposal ahead of the law's January 2027 enactment, with applications from stablecoin issuers expected to be processed starting that year. The GENIUS Act, signed into law in July 2025, establishes a federal framework for payment stablecoins. While several agencies have published proposals, the OCC's upcoming final rule is seen as a key step to provide regulatory clarity before the deadline.

US Comptroller of the Currency Jonathan Gould said that his agency would have final rules related to the implementation of a payment stablecoin law out by November.

Speaking at the Wyoming Blockchain Symposium on Wednesday, the regulator said that following the Office of the Comptroller of the Currency’s (OCC’s) proposal to implement the Guiding and Establishing National Innovation for US Stablecoins (GENIUS) Act, OCC would release finalized rules ahead of the law’s scheduled January 2027 enactment.

Gould said that the OCC “will have a final rule out by November” as the agency considered feedback from the crypto industry following the release of its proposed rules in February. He added that he expects the regulator could begin processing applications related to stablecoin issuers starting in 2027.

The GENIUS Act, signed into law in July 2025, aims to create a regulatory framework for payment stablecoins in the US, requiring rules from the government agencies overseeing the products, including the OCC, Treasury Department, Federal Deposit Insurance Corporation (FDIC) and the Federal Reserve Board.

Although the OCC moved forward with a 376‐page proposal to implement GENIUS in February, government agencies have only until Jan. 18 to finalize regulations as the law goes into effect. Several regulators have already published proposals and collected public feedback related to the implementation of GENIUS, but did not release finalized rules by July, potentially resulting in regulatory uncertainty for stablecoin issuers.

Related: OCC approves Trump family crypto company for trust charter

Criptos en tendencia

CitreaCTR

wrapped stUSDTWSTUSDT

Preguntas relacionadas

QWhat is the GENIUS Act, and what is its primary goal?

AThe GENIUS Act, signed into law in July 2025, is the Guiding and Establishing National Innovation for US Stablecoins Act. Its primary goal is to create a regulatory framework for payment stablecoins in the United States.

QWho is Jonathan Gould, and what promise did he make regarding the GENIUS Act rules?

AJonathan Gould is the US Comptroller of the Currency. He promised that the Office of the Comptroller of the Currency (OCC) would have final rules implementing the GENIUS Act published by November.

QWhen is the GENIUS Act scheduled to go into effect, and by what date must agencies finalize their regulations?

AThe GENIUS Act is scheduled to go into effect in January 2027. Government agencies have until January 18, 2027, to finalize their regulations as stipulated by the law.

QWhich US government agencies are tasked with creating rules for the GENIUS Act?

AThe agencies tasked with creating rules for the GENIUS Act include the Office of the Comptroller of the Currency (OCC), the Treasury Department, the Federal Deposit Insurance Corporation (FDIC), and the Federal Reserve Board.

QWhen does OCC head Jonathan Gould expect the agency to begin processing applications from stablecoin issuers?

AJonathan Gould expects the OCC could begin processing applications related to stablecoin issuers starting in 2027, following the law's enactment.

Lecturas Relacionadas

Github's 10k-Star Agent Platform 'Instant' Acquired by OpenAI, Entire Team Joins, Hailed as 'AI-Era Firebase'

OpenAI has acquired the entire team of Instant, a YC S22 startup known as the "Firebase for the AI era." Instant's core product provides backend infrastructure—including databases, authentication, real-time sync, and offline caching—specifically designed for AI Agents. The acquisition aims to solve a critical weakness in current AI Agents: their lack of persistent memory and state management, which hinders reliable, multi-agent collaboration and long-running workflows. Instant, founded by ex-Facebook and Airbnb engineers, had gained significant traction with over 10,000 GitHub stars, 17,000 developers, and 400,000 apps built on its platform. This move is part of OpenAI's broader 2026 strategy to aggressively acquire developer infrastructure companies. By integrating tools like Instant, OpenAI is evolving from a model provider into a comprehensive AI platform, aiming to create a fully integrated ecosystem for building and deploying AI applications.

marsbitHace 4 min(s)

Github's 10k-Star Agent Platform 'Instant' Acquired by OpenAI, Entire Team Joins, Hailed as 'AI-Era Firebase'

marsbitHace 4 min(s)

Three Months After the Passing of Little Dog Rosie, Her Medical Records Transformed into an AI Healthcare Company

Three months after the passing of his dog Rosie, AI entrepreneur Paul S. Conyngham secured $4 million in seed funding from Founders Fund for his new startup, Gamgee. The company aims to industrialize the experimental, AI-assisted process he pioneered to create a personalized mRNA cancer vaccine for Rosie, who suffered from mast cell tumors. With no formal biology background, Conyngham used AI tools like ChatGPT and AlphaFold to analyze Rosie's tumor DNA, identify target neoantigens, and design a custom mRNA vaccine sequence. Laboratory partners at UNSW produced the vaccine. Initial treatment showed tumor reduction, but Rosie's cancer later recurred and she was euthanized. Gamgee's goal is to streamline this "N-of-1" approach into a repeatable service for canine cancer patients, handling sequencing, vaccine design, production, and delivery. Clinical trials are planned in Australia in collaboration with research institutions. The company also eyes a longer-term vision of establishing personalized, mRNA-based medicine across species. The story highlights the broader challenge in personalized cancer treatment: compressing the entire timeline from design and regulatory approval to manufacturing and administration to match the patient's prognosis. While AI can accelerate target discovery, the remaining logistical and regulatory hurdles are significant. The article concludes by emphasizing that, for now, consulting qualified veterinary oncologists remains the responsible path for pet owners.

marsbitHace 5 min(s)

Three Months After the Passing of Little Dog Rosie, Her Medical Records Transformed into an AI Healthcare Company

marsbitHace 5 min(s)

mRNA Vaccine Too Slow, Dog Owner Loses Beloved Pet, World's First AI-Customized Dog Cancer Vaccine Arrives

A heartbreaking story from Australia showcases the intersection of AI, love, and loss. Paul Conyngham, an AI expert, lost his beloved bull terrier Rosie to cancer in 2024. Refusing to accept her prognosis, he used his machine learning skills, ChatGPT, and AlphaFold to design a personalized mRNA vaccine targeting her specific cancer mutations. The first vaccine dose, synthesized with help from university scientists, shrank Rosie's tumor by 75%, granting her a temporary reprieve. However, the cancer recurred with new mutations, requiring a second, updated vaccine. The traditional, slow production process couldn't deliver it in time, and Rosie passed away. Determined to prevent similar tragedies, Paul founded Gamgee, a startup named after a "Lord of the Rings" character. Backed by $4 million in seed funding from Founders Fund, Y Combinator, and others, Gamgee aims to industrialize and democratize personalized canine cancer vaccines. Their vision is an end-to-end platform where veterinarians submit tumor samples, AI algorithms rapidly identify target mutations, and customized mRNA vaccines are produced. The goal is to slash the design time to 48 hours and the total cost to around $2,000 per treatment. The addressable market is vast, with about 6 million dogs diagnosed with cancer annually in the US alone. Beyond pets, Gamgee's "N-of-1" medicine approach, validated in dogs, paves the way for similar ultra-personalized cancer therapies for humans, a field recently energized by Moderna's successful AI-designed mRNA vaccine trial for melanoma. Rosie's legacy lives on, fueling a mission to turn personalized hope into scalable, timely reality for millions.

marsbitHace 10 min(s)

mRNA Vaccine Too Slow, Dog Owner Loses Beloved Pet, World's First AI-Customized Dog Cancer Vaccine Arrives

marsbitHace 10 min(s)

Not Being a Follower of Silicon Valley: A Few Young PhD Students Bet on the Integrated Brain of Bipedal Humanoid Robots

This article profiles GongShengZhiXing, a startup founded by 1996-born Ding Pengxiang with a core team of Ph.D. students, all in their twenties. They are developing an end-to-end, integrated "brain" (base model) for bipedal humanoid robots, focusing on full-body dynamic coordination rather than the industry's more common modular, layered approach. The team's stance is that for humanoids to integrate into human environments, an end-to-end model—where a single system handles perception, decision-making, and control directly—is ultimately more efficient and scalable than layered architectures that separate high-level "brain" and low-level "cerebellum" functions. They argue layered systems create information bottlenecks. A key demo shows their robot driving a go-kart at high speed, demonstrating synchronized hand-eye-foot coordination and multi-contact balance—a complex task highlighting their focus on whole-body dynamics over simple kinematics. Technically, their model outputs commands at the joint level and incorporates a "Motion Expert" module and techniques like DriftDistill to simultaneously learn task completion and physical stability from data. Acknowledging challenges like severe data scarcity for full-body mobile manipulation, they employ methods like TrajBooster to synthesize training data. Ding Pengxiang believes true "emergence" of new skills at the joint-movement level is the goal, but commercial viability likely requires scaling to millions of training hours. The team aims not to follow Silicon Valley trends but to pioneer and potentially set global standards in this nascent, unconverged field of embodied AI.

marsbitHace 11 min(s)

Not Being a Follower of Silicon Valley: A Few Young PhD Students Bet on the Integrated Brain of Bipedal Humanoid Robots

marsbitHace 11 min(s)

00s Postgraduate from Tsinghua University Starts Business on 'Neural Interface': Turning Human Muscle Reactions into Tokens

Title: "Post-00s Tsinghua PhD Student Founds Startup 'Neuro Interface': Turning Human Muscle Responses into Tokens" Summary: OriginFlow, a startup founded by 2001-born Tsinghua PhD candidate Qin Shentao, is pioneering a new approach for embodied AI data collection using non-invasive surface electromyography (sEMG). Their NeuroScale system employs a wristband (OriginKitGen 1.0) to capture neural signals from forearm muscles, which are then fused with first-person vision and IMU data. A base model called PULSE reconstructs hand poses, contact forces, and tendon dynamics from these signals, encoding them into standardized "Human Tokens"—a foundational representation for physical interaction data aimed at training robots. This method addresses the scarcity of high-quality physical interaction data in embodied AI. The company has secured over 500 million RMB in funding and outlines a three-phase vision: collecting human motion data (From Human), creating always-on AI hardware (With Human), and ultimately augmenting human capabilities (Enhance Human). OriginFlow aims to scale data collection to "trillions of hours" by making devices unobtrusive enough for daily wear.

marsbitHace 31 min(s)

00s Postgraduate from Tsinghua University Starts Business on 'Neural Interface': Turning Human Muscle Reactions into Tokens

marsbitHace 31 min(s)

Trading

Spot

Artículos destacados

Cómo comprar GENIUS

¡Bienvenido a HTX.com! Hemos hecho que comprar Genius (GENIUS) sea simple y conveniente. Sigue nuestra guía paso a paso para iniciar tu viaje de criptos.Paso 1: crea tu cuenta HTXUtiliza tu correo electrónico o número de teléfono para registrarte y obtener una cuenta gratuita en HTX. Experimenta un proceso de registro sin complicaciones y desbloquea todas las funciones.Obtener mi cuentaPaso 2: ve a Comprar cripto y elige tu método de pagoTarjeta de crédito/débito: usa tu Visa o Mastercard para comprar Genius (GENIUS) al instante.Saldo: utiliza fondos del saldo de tu cuenta HTX para tradear sin problemas.Terceros: hemos agregado métodos de pago populares como Google Pay y Apple Pay para mejorar la comodidad.P2P: tradear directamente con otros usuarios en HTX.Over-the-Counter (OTC): ofrecemos servicios personalizados y tipos de cambio competitivos para los traders.Paso 3: guarda tu Genius (GENIUS)Después de comprar tu Genius (GENIUS), guárdalo en tu cuenta HTX. Alternativamente, puedes enviarlo a otro lugar mediante transferencia blockchain o utilizarlo para tradear otras criptomonedas.Paso 4: tradear Genius (GENIUS)Tradear fácilmente con Genius (GENIUS) en HTX's mercado spot. Simplemente accede a tu cuenta, selecciona tu par de trading, ejecuta tus trades y monitorea en tiempo real. Ofrecemos una experiencia fácil de usar tanto para principiantes como para traders experimentados.

634 Vistas totalesPublicado en 2026.04.29Actualizado en 2026.06.02

Discusiones

Bienvenido a la comunidad de HTX. Aquí puedes mantenerte informado sobre los últimos desarrollos de la plataforma y acceder a análisis profesionales del mercado. A continuación se presentan las opiniones de los usuarios sobre el precio de GENIUS (GENIUS).